Tags: Arthritis | arthritis | drug | rheumatoid | study

New Arthritis Drug Succeeds in Study

New Arthritis Drug Succeeds in Study
(Copyright Fotolia)

Wednesday, 06 June 2018 07:43 AM

Abbvie Inc said on Tuesday its experimental drug met the main goal of halting progression of moderate-to-severe rheumatoid arthritis in a late-stage trial.

The drug, upadacitinib, was tested as a monotherapy in patients who have not been treated with chemotherapy agent methotrexate.

Upadacitinib, which belongs to a class of drugs known as JAK inhibitors, also helped improve symptoms of the disease such as swollen joint counts, the company said, adding it plans to submit a U.S. marketing application in the second half of 2018.

AbbVie, whose drug Humira is the market-leading treatment for rheumatoid arthritis, is among drugmakers developing JAK inhibitors, which work by blocking inflammation-causing enzymes known as Janus kinases.

Last week, the Food and Drug Administration approved lower doses of another JAK inhibitor developer by Eli Lilly and Incyte Corp, but gave it a label that analysts said could restrict its potential for use in a larger population.

© 2020 Thomson/Reuters. All rights reserved.

   
1Like our page
2Share
Health-News
Abbvie Inc said on Tuesday its experimental drug met the main goal of halting progression of moderate-to-severe rheumatoid arthritis in a late-stage trial. The drug, upadacitinib, was tested as a monotherapy in patients who have not been treated with chemotherapy agent...
arthritis, drug, rheumatoid, study
150
2018-43-06
Wednesday, 06 June 2018 07:43 AM
Newsmax Media, Inc.
 

The information presented on this website is not intended as specific medical advice and is not a substitute for professional medical treatment or diagnosis. Read Newsmax Terms and Conditions of Service.

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

NEWSMAX.COM
© Newsmax Media, Inc.
All Rights Reserved